0QZU Overzicht aandelen Vertex Pharmaceuticals Incorporated, een biotechnologiebedrijf, houdt zich bezig met de ontwikkeling en verkoop van therapieën voor de behandeling van taaislijmziekte (CF). Meer informatie
Beloningen Risicoanalyse Geen risico's gedetecteerd voor 0QZU uit onze risicocontroles.
Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Vertex Pharmaceuticals Incorporated Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Vertex Pharmaceuticals Historische aandelenkoersen Huidige aandelenkoers US$405.26 52 Week Hoogtepunt US$519.66 52 Week Laag US$378.12 Bèta 0.37 1 maand verandering -11.80% 3 maanden verandering -10.57% 1 Jaar Verandering -2.79% 3 jaar verandering 82.30% 5 jaar verandering 77.26% Verandering sinds IPO 266.72%
Recent nieuws en updates
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09
Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023) Nov 05
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Nov 05
Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024 Oct 11 Meer updates bekijken
Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Trialta® (elexacaftor/ivacaftor andivacaftor) to Include Additional Non-F508del TrialKAFTA-Responsive Variants Dec 21
Vertex Pharmaceuticals Incorporated Announces Results from Phase 2 Study of Suzetrigine for Treatment of Painful Lumbosacral Radiculopathy Dec 19
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on Casgevy at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update Dec 09
Third quarter 2024 earnings released: EPS: US$4.05 (vs US$4.01 in 3Q 2023) Nov 05
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Nov 05
Vertex Pharmaceuticals Incorporated to Report Q3, 2024 Results on Nov 04, 2024 Oct 11
Second quarter 2024 earnings released: US$13.92 loss per share (vs US$3.55 profit in 2Q 2023) Aug 02
Vertex Pharmaceuticals Incorporated Raises Earnings Guidance for the Full Year 2024 Aug 02
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-To-Severe Acute Pain Jul 31 Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for Trikafa® for People with Cystic Fibrosis Aged 2 Years and Older with Certain Rare Mutations Jul 16
Vertex Pharmaceuticals Incorporated to Report Q2, 2024 Results on Aug 01, 2024
Vertex Pharmaceuticals, Inc. Announces Positive Results from Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Jun 22
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) completed the acquisition of Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders. May 21
Vertex Pharmaceuticals Incorporated Appoints Jennifer Schneider as Independent Director May 16
Vertex Pharmaceuticals Incorporated Re-Iterates Earnings Guidance for the Full Year 2024 May 08
First quarter 2024 earnings released: EPS: US$4.26 (vs US$2.72 in 1Q 2023) May 07
Vertex Pharmaceuticals Announces European Commission Approval for KALYDECO to Treat Infants with Cystic Fibrosis Ages 1 Month and Older Apr 27
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into an agreement to acquire Alpine Immune Sciences, Inc. (NasdaqGM:ALPN) from a group of shareholders for approximately $4.3 billion. Apr 11
Vertex Pharmaceuticals Incorporated to Report Q1, 2024 Results on May 06, 2024 Apr 10
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 15, 2024 Apr 05 Vertex Pharmaceuticals Incorporated Announces New Drug Submission for Exagamglogene Autotemcel (Exa-Cel) Accepted for Priority Review by Health Canada for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
Vertex Pharmaceuticals Receives CHMP Positive Opinion for KALYDECO for the Treatment of Infants with Cystic Fibrosis Ages 1 Month and Older Feb 23
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Feb 13
Vertex Pharmaceuticals Incorporated Announces Positive Results from Pivotal Trials of Vanza Triple Combination Treatment for Cystic Fibrosis Feb 07
Vertex Pharmaceuticals Incorporated Provides Product Revenue Guidance for the Full Year 2024 Feb 06
Full year 2023 earnings released: EPS: US$14.05 (vs US$12.97 in FY 2022) Feb 06
Vertex Announces Positive Results from the VX-548 Phase 3 Program for the Treatment of Moderate-To-Severe Acute Pain Jan 30
Vertex Pharmaceuticals Incorporated to Report Q4, 2023 Results on Feb 05, 2024 Jan 18
Vertex Pharmaceuticals Incorporated Announces US FDA Approval of CASGEVY™ (Exagamglogene Autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia Jan 17
Vertex Pharmaceuticals Incorporated Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Kingdom of Saudi Jan 10
Vertex Pharmaceuticals Incorporated Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Dec 16
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy Dec 14 CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States
Vertex Pharmaceuticals Incorporated Appoints Nancy Thornberry to Its Board of Directors as an Independent Director Dec 06
Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 2 Months and Older Nov 30
Vertex Pharmaceuticals Incorporated Announces European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5 Nov 24
Vertex Pharmaceuticals Incorporated Announces United Kingdom Medicines and Healthcare Products Regulatory Agency Granted Conditional Marketing Authorization for CASGEVY Nov 17
Third quarter 2023 earnings released: EPS: US$4.01 (vs US$3.63 in 3Q 2022) Nov 08
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Market Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 To 5 Years With at Least One F508del Mutation Oct 18
Vertex Pharmaceuticals Incorporated to Report Q3, 2023 Results on Nov 06, 2023 Oct 11
Vertex Pharmaceuticals Incorporated Appoints Michel Lagarde to Its Board of Directors Oct 06
Vertex Pharmaceuticals Incorporated Receives Chmp Positive Opinion for Kaftrio® (Ivacaftor/Tezacaftor/Elexacaftor) in Combination with Ivacaftor for Children with Cystic Fibrosis Ages 2 Through 5 Sep 16
Vertex Pharmaceuticals Incorporated Appoints E. Morrey Atkinson, Ph.D., as Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations Aug 30
Vertex Pharmaceuticals Incorporated Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine Aug 04
Second quarter 2023 earnings released: EPS: US$3.55 (vs US$3.17 in 2Q 2022) Aug 02
Vertex Pharmaceuticals Incorporated Announces European Commission Approval for ORKAMBI® (Lumacaftor/Ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 1 to <2 Years Old Jul 06
Insufficient new directors Jul 01
Vertex Pharmaceuticals Incorporated Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the American Diabetes Association 83rd Scientific Sessions Jun 24
Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Jun 10
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Jun 09
First quarter 2023 earnings released: EPS: US$2.72 (vs US$2.99 in 1Q 2022) May 03
Full year 2022 earnings released: EPS: US$12.97 (vs US$9.09 in FY 2021) Feb 08
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $3,000 million worth of its shares. Feb 08
Vertex Pharmaceuticals Incorporated to Report Q4, 2022 Results on Feb 07, 2023 Jan 18
Vertex Pharmaceuticals Incorporated Announces to Present New Data on its Portfolio of Cystic Fibrosis Medicines at 2022 North American Cystic Fibrosis Conference Nov 04
Third quarter 2022 earnings released: EPS: US$3.63 (vs US$3.30 in 3Q 2021) Oct 28
Vertex Pharmaceuticals Incorporated Revises Revenue Guidance for the Fiscal 2022 Oct 28
Vertex Pharmaceuticals Incorporated to Report Q3, 2022 Results on Oct 27, 2022 Oct 14
Vertex Pharmaceuticals Incorporated Advances Program Targeting Alpha-1 Antitrypsin Deficiency Oct 12
Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022 Sep 28
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 10
Vertex Pharmaceuticals Incorporated Appoints Jonathan Biller as Chief Legal Officer, Effective September 19, 2022 Sep 09
Vertex Announces U.S. FDA Approval for Orkambi® (Lumacaftor/Ivacaftor) in Children with Cystic Fibrosis Ages 12 to <24 Months Sep 03
Second quarter 2022 earnings released: EPS: US$3.17 (vs US$0.26 in 2Q 2021) Aug 05
Vertex Pharmaceuticals Incorporated Reports Unaudited Intangible Asset Impairment Charge for the Three Months Ended June 30, 2022 Aug 05
Vertex Advances VX-548 in Acute and Neuropathic Pain Jul 23
Vertex Pharmaceuticals Incorporated to Report Q2, 2022 Results on Aug 04, 2022 Jul 19
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 13
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) entered into a definitive agreement to acquire ViaCyte, Inc. from Sanderling Ventures, RA Capital Management, L.P., The Invus Group, LLC, Asymmetry Ventures LLC and others for approximately $320 million. Jul 12
Vertex Announces FDA Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes Jul 06
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Jun 11
Vertex Pharmaceuticals Incorporated Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA Jun 09
Vertex Pharmaceuticals Incorporated to Present New Data on VX-880 Clinical Trial Jun 01
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 25
Vertex Pharmaceuticals Incorporated (NasdaqGS : VRTX) acquired Complement Portfolio of Catalyst Biosciences, Inc. for $60 million. May 24
Vertex Pharmaceuticals Incorporated Elects Suketu Upadhyay as Independent Director May 19
First quarter 2022 earnings released: EPS: US$2.99 (vs US$2.52 in 1Q 2021) May 06
Vertex Pharmaceuticals Incorporated Reiterates Earning Guidance for 2022 May 06
Vertex Pharmaceuticals Incorporated to Report Q1, 2022 Results on May 05, 2022 Apr 22
Vertex Pharmaceuticals Incorporated Announces Health Canada Grants Marketing Authorization for TRIKAFTA in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation Apr 21
Vertex Pharmaceuticals Incorporated, Annual General Meeting, May 18, 2022 Apr 08
Vertex Pharmaceuticals Incorporated Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain Apr 01
Vertex Pharmaceuticals Incorporated Announces Reimbursement Agreement in Australia for TRIKAFTA Mar 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Jan 27
Vertex Pharmaceuticals Incorporated Provides Full Year 2022 Financial Guidance Jan 27
Vertex Pharmaceuticals Incorporated announces European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) Jan 12
Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis Dec 02
Third quarter 2021 earnings released: EPS US$3.30 (vs US$2.56 in 3Q 2020) Nov 03
Vertex Pharmaceuticals Incorporated Announces Its Supplement to a New Drug Submission for PrKALYDECO Sep 24
Vertex Pharmaceuticals Incorporated Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis Aug 27
CEO, President & Director recently bought US$2.0m worth of stock Aug 25
Lead Independent Director recently bought US$3.0m worth of stock Aug 05
Second quarter 2021 earnings released: EPS US$0.26 (vs US$3.23 in 2Q 2020) Jul 31
Vertex Pharmaceuticals Incorporated Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain Jul 20
Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX) announces an Equity Buyback for $1,500 million worth of its shares. Jun 25 Rendement voor aandeelhouders 0QZU GB Biotechs GB Markt 7D -1.1% 3.3% 1.3% 1Y -2.8% -23.4% 4.3%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: 0QZU overtrof de UK Biotechs industrie, die het afgelopen jaar een rendement -23.4 % opleverde.
Rendement versus markt: 0QZU presteerde slechter dan UK Market , dat het afgelopen jaar een rendement van 4.3 % opleverde.
Prijsvolatiliteit Is 0QZU's price volatile compared to industry and market? 0QZU volatility 0QZU Average Weekly Movement 5.3% Biotechs Industry Average Movement 9.8% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.5% 10% least volatile stocks in GB Market 2.6%
Stabiele aandelenkoers: 0QZU heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van 0QZU is het afgelopen jaar stabiel geweest.
Over het bedrijf Opgericht Werknemers CEO Website 1989 5,400 Reshma Kewalramani www.vrtx.com
Vertex Pharmaceuticals Incorporated, een biotechnologiebedrijf, houdt zich bezig met de ontwikkeling en commercialisering van therapieën voor de behandeling van taaislijmziekte (CF). Het brengt TRIKAFTA/KAFTRIO op de markt voor mensen met CF met ten minste één F508del-mutatie vanaf 2 jaar; SYMDEKO/SYMKEVI voor mensen met CF vanaf 6 jaar; ORKAMBI voor CF-patiënten vanaf 1 jaar; en KALYDECO voor de behandeling van patiënten met CF vanaf 1 jaar met ivacaftor. De pijplijn van het bedrijf omvat VX-522, een CFTR mRNA therapeuticum ontworpen om de onderliggende oorzaak van CF te behandelen, dat zich in Fase 1 van het klinisch onderzoek bevindt; VX-548, een niet-opioïde geneesmiddel voor de behandeling van acute en neuropathische pijn, dat zich in Fase 3 van het klinisch onderzoek bevindt; Exa-cel, voor de behandeling van sikkelcelziekte en transfusie-afhankelijke bèta thalassemie, dat zich in Fase 2/3 van het klinisch onderzoek bevindt.
Meer tonen Vertex Pharmaceuticals Incorporated Samenvatting Hoe verhouden de winst en inkomsten van Vertex Pharmaceuticals zich tot de beurswaarde? 0QZU fundamentele statistieken Marktkapitalisatie US$103.71b Inkomsten(TTM ) -US$479.80m Inkomsten(TTM ) US$10.63b
9.8x P/S-verhouding
-217.8x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 0QZU resultatenrekening (TTM ) Inkomsten US$10.63b Kosten van inkomsten US$4.93b Brutowinst US$5.69b Overige uitgaven US$6.17b Inkomsten -US$479.80m
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -1.86 Brutomarge 53.59% Nettowinstmarge -4.52% Schuld/Eigen Vermogen Verhouding 0%
Hoe presteerde 0QZU op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2025/01/02 07:30 Aandelenkoers aan het einde van de dag 2025/01/02 00:00 Inkomsten 2024/09/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Vertex Pharmaceuticals Incorporated wordt gevolgd door 75 analisten. 32 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Jasper Hellweg Argus Research Company Brian Skorney Baird Ishan Majumdar Baptista Research
Toon 72 meer analisten 
